Navigation Links
WuXi PharmaTech Announces Second Quarter 2007 Results
Date:9/5/2007

ermediates and active pharmaceutical ingredients for R&D use. In 2006, WuXi PharmaTech provided services to 70 pharmaceutical and biotechnology customers, including nine of the top ten pharmaceutical companies in the world, as measured by 2006 total revenues. For more information, please visit: http://www.wuxipharmatech.com .

Use of Non-GAAP Financial Measures

WuXi PharmaTech has provided the second quarter of 2007 net income and earnings per ADS on a non-GAAP basis, all excluding share-based compensation expenses. The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing the Company's financial performance and liquidity and when planning and forecasting future periods. These non-GAAP operating measures are useful for understanding and assessing underlying business performance and operating trends. The Company expects to provide net income and earnings per ADS on a non-GAAP basis using a consistent method on a quarterly basis going forward.

Readers are cautioned not to view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies, and should refer to the reconciliation of non-GAAP measures to GAAP measures for the indicated periods attached hereto.

Cautionary Note Regarding Forward-Looking Statements

Statements in this release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995, including, among others, WuXi PharmaTech's anticipated operating results for 2007, our expansion plan for the Jinshan manufacturing facility and the design of our new preclinical drug safety evaluation center in Suzhou. These forward- lo
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Physicians Choice Laboratory ... pharmacogenetics menu, which enables healthcare providers to individualize ... PCLS’s evidence-based results, healthcare providers are better able ... therapy, while minimizing risks for adverse drug reactions ... to the FDA [1] more than 2.2 million ...
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... announced next steps for its Oral Amphotericin B ... its in vitro work involving samples ... now plans to complete pre clinical studies and ... Phase 1A clinical trial, utilizing approximately $700,000 of ...
(Date:10/22/2014)... KONG , Oct. 22, 2014  aTyr Pharma ... that rare disease expert John C. McKew , ... McKew brings more than two decades of expertise in ... Institutes of Health, Wyeth Research and Genetics Institute, Inc. ... aTyr,s efforts to expand and translate its novel Physiocrine ...
(Date:10/20/2014)... 2014 Convey Computer , the ... from Iowa State University won first place in the ... Convey HC-2ex, the team’s solution achieved the highest overall ... the second place finisher. , Experts from all segments ... month long challenge, using a variety of design tools, ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... a privately-held biotech company using its proprietary platform technology ... gastrointestinal diseases, announced today that it has elected Christopher ... Inc. to its Board of Directors. ... on our Board," said Dr. Barbara Fox, founder, CEO ...
... Inc. (Nasdaq: SGMO ) today announced that the ... Wednesday, May 2, 2012, after the market closes. The press ... p.m. ET, which will be open to the public via ... review the financial results and discuss other business matters. ...
... 2012 The rise of the corporate ... investing are emerging key themes at BioTrinity, the-premier European ... business network which provides comprehensive support for bioscience businesses ... The first day of the conference saw ...
Cached Biology Technology:Avaxia Biologics Elects Christopher Kiritsy to its Board of Directors 2Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast 2Corporate Venturing and Early-Stage Financing in the Spotlight at BioTrinity 2Corporate Venturing and Early-Stage Financing in the Spotlight at BioTrinity 3
(Date:10/16/2014)... Institute of Marine Science have received a 3-year, ... identify the streams and wetlands most vulnerable to ... local governments and citizens conserve these important ecosystems. ... of tidal-marsh observations first gathered by VIMS scientists ... can today,s researchers accurately map the slow but ...
(Date:10/16/2014)... monocultures can be cultivated efficiently, they are anything ... caused by monoculture cultivation is becoming increasingly evident. ... crop form and are regarded as the sole ... – quite wrongfully, finds Bernhard Schmid, an ecology ... a novel form of agriculture and forestry. After ...
(Date:10/16/2014)... , October 16, 2014 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... leading edge technologies including Wocket™, the Smart Wallet, at ... Conferenece. FiRe is a leading global conference on the ... Hosted by Mark Anderson , founder and publisher ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... Do you find yourself leading groups, or are you ... if you want to be a leader you,re better off ... middle of the action. In a series of experiments ... Biological Sciences at the University of Leeds also found that ...
... of new neurons in the adult brain is well known. ... structure lining the lateral ventricles. This is where neural or ... neurons if needed. For many years now, the subventricular zone ... brain tumors called gliomas, the most deadly type of which ...
... attacks by herbivores or pathogens by activating defense programs ... defense responses require a great deal of the plant,s ... growth and reproduction. So, it,s very important to strictly ... the jasmonates, are crucial in this process and ...
Cached Biology News:Follow the leader: How those in charge make themselves known 2Brain tumors: Tissue stem cell turning into tumor stem cell 2Biologists discover an on/off button on plants' alarm system 2
Mouse monoclonal [RIZ1723] to PRDM2/RIZ...
... OA-Hy cis- 9-Octadecenoyl-N-hydroxylamide ... LIGHT. PACKAGED UNDER INERT GAS. A potent ... dose-dependent manner (K i = 1.7 ... Soluble in EtOH or DMSO. Unstable in ...
... early protein. Can detect ... exhibiting an intranuclear inclusion staining ... 6-24 hours. These antibodies ... staining. No other nuclear ...
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
Biology Products: